REPL

Replimune Group

• Seeking Alpha·2d ago

  Iovance Biotherapeutics: Positioned For Multi-Year Growth, Buy The Pullback

• Reuters·2d ago

  Replimune Chief Commercial Officer Christopher Sarchi sells USD 52,065 common shares

• Seeking Alpha·5d ago

  Catalyst Watch: OPEC meeting, FedEx talks freight, inflation reads, and SpaceX IPO buzz

• NASDAQ·03/30 16:16

  RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare Disease

• Seeking Alpha·03/18 00:54

  Tracking Baker Brothers Portfolio - Q4 2025 Update

• TipRanks·03/16 11:25

  Replimune: Binary RP1 PDUFA Outcome and Funding Overhang Justify Hold Rating

• The Wall Street Journal·03/09 17:15

  Biotech Stocks Rally on Departure of Polarizing FDA Official

• Seeking Alpha·03/09 13:40

  Biotech firm stocks rise on FDA vaccine head’s exit

• TipRanks·03/03 12:52

  FDA review process for accelerated approval narrows, less predictable, WSJ says

• The Wall Street Journal·03/03 10:30

  MAHA Is Bringing Chaos to Biotech Investment Beyond Just Vaccines -- Heard on the Street

• Reuters·03/02 13:01

  Replimune management to present at Leerink Partners Global Healthcare Conference and host investor meetings at Jefferies Biotech on the Beach Summit

• Seeking Alpha·02/21 04:46

  Replimune: Multiple Shots On Goal But A High Risk Binary Approaches

• Dow Jones·02/05 15:59

  Replimune Group Price Target Raised to $14.00/Share From $13.00 by Piper Sandler

• Dow Jones·02/05 15:59

  Replimune Group Is Maintained at Overweight by Piper Sandler

• Dow Jones·02/04 14:45

  Replimune Group Is Maintained at Outperform by Wedbush